Novel therapies focused on the high-density lipoprotein particle (Q26823249)

H. Bryan Brewer

series ordinal

2

1 reference

John J.P. Kastelein

series ordinal

3

1 reference

language of work or name

1 reference

3 January 2014

1 reference

1 reference

114

1 reference

PubMed

issue

1

1 reference

PubMed

page(s)

193-204

1 reference

Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels

PubMed

cites work

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Major lipids, apolipoproteins, and risk of vascular disease

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL.

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies.

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Mechanism of action of niacin

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

The apolipoprotein A-I mimetic peptide ETC-642 exhibits anti-inflammatory properties that are comparable to high density lipoproteins

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Antiatherogenic effects of newly developed apolipoprotein A-I mimetic peptide/phospholipid complexes against aortic plaque burden in Watanabe-heritable hyperlipidemic rabbits.

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Recombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-type).

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Increased risk of coronary artery disease in Caucasians with extremely low HDL cholesterol due to mutations in ABCA1, APOA1, and LCAT.

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Intestinal specific LXR activation stimulates reverse cholesterol transport and protects from atherosclerosis

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers.

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Carriers of lecithin cholesterol acyltransferase gene mutations have accelerated atherogenesis as assessed by carotid 3.0-T magnetic resonance imaging [corrected]

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Emerging high-density lipoprotein infusion therapies: fulfilling the promise of epidemiology?

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Apolipoprotein mimetic peptides: Mechanisms of action as anti-atherogenic agents

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

PPARs at the crossroads of lipid signaling and inflammation

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides.

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Reciprocal regulation of inflammation and lipid metabolism by liver X receptors

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Novel HDL-directed pharmacotherapeutic strategies

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR.

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Effects of combination lipid therapy in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Safety of anacetrapib in patients with or at high risk for coronary heart disease

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Effects of dalcetrapib in patients with a recent acute coronary syndrome

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Synthetic LXR ligand inhibits the development of atherosclerosis in mice

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Discovery of chemical inhibitors of the selective transfer of lipids mediated by the HDL receptor SR-BI.

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Torcetrapib impairs endothelial function in hypertension

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

1 reference

7 January 2021

Low dose of the liver X receptor agonist, AZ876, reduces atherosclerosis in APOE*3Leiden mice without affecting liver or plasma triglyceride levels.

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

MiR-33 contributes to the regulation of cholesterol homeostasis.

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Changes in HDL cholesterol and cardiovascular outcomes after lipid modification therapy

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Recombinant apolipoprotein A-I(Milano) infusion into rabbit carotid artery rapidly removes lipid from fatty streaks.

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Macrophage reverse cholesterol transport in mice expressing ApoA-I Milano

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro.

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Heart disease and stroke statistics--2012 update: a report from the American Heart Association

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Liver x receptors in atherosclerosis and inflammation

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Compromised LCAT function is associated with increased atherosclerosis

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Functional lecithin: cholesterol acyltransferase is not required for efficient atheroprotection in humans

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function.

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

A novel approach to oral apoA-I mimetic therapy

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Characterization and properties of pre beta-HDL particles formed by ABCA1-mediated cellular lipid efflux to apoA-I.

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE*3Leiden mice: time course and mechanisms

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Lecithin:cholesterol acyltransferase: old friend or foe in atherosclerosis?

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

The promise of cholesteryl ester transfer protein (CETP) inhibition in the treatment of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk

1 reference

https://api.crossref.org/works/10.1161%2FCIRCRESAHA.114.301804

7 January 2021

10.1161/CIRCRESAHA.114.301804

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

4419303

4419303

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference